(NYSE: MDT) is a stock I bought and have added to several times. I'm not a healthcare-focused investor, but the stock's historically high 3.6% dividend yield and long history of annual dividend increases were too much to ignore. Looking at the negative news around the stock largely centered around how new weight loss drugs might affect its sales, I think Medtronic is still a strong buy.

From a big-picture perspective, roughly-$100-billion-market-cap Medtronic is a giant in the medical device space. Its portfolio spans across multiple industry niches, including cardiovascular health, neuroscience, medical-surgical, and diabetes. The company is a notable player in all of the areas in which it competes.

Image source: Getty Images.

Continue reading

Source Fool.com